Contrasting ImmuCell (NASDAQ:ICCC) and CompuMed (OTCMKTS:CMPD)

CompuMed (OTCMKTS:CMPD) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CompuMed and ImmuCell, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CompuMed	0	0	0	0	0.00
ImmuCell	1	0	0	0	1.00

Insider and Institutional Ownership

13.5% of ImmuCell shares are held by institutional investors. 22.0% of CompuMed shares are held by company insiders. Comparatively, 5.6% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

CompuMed has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.

Earnings & Valuation

This table compares CompuMed and ImmuCell”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CompuMed	$6.22 million	0.67	$30,000.00	$0.12	26.25
ImmuCell	$27.77 million	1.55	-$2.16 million	$0.26	18.25

CompuMed has higher earnings, but lower revenue than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than CompuMed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CompuMed and ImmuCell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CompuMed	2.27%	4.83%	3.33%
ImmuCell	6.23%	6.25%	3.87%

Summary

ImmuCell beats CompuMed on 9 of the 12 factors compared between the two stocks.

About CompuMed

CompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. It offers telecardiology and teleradiology services that provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities worldwide. The company also provides enterprise telemedicine solutions; a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including electrocardiogram (ECG) devices, echocardiogram, ECG, vascular, holter, nuclear, and video consults; and reading, transcription, reporting, storage, and video consultations in the areas of Vscan, X-ray, ultrasound, mammography, computed tomography, magnetic resonance imaging, and radiologist video consults. It also offers OsteoGram software that works in combination with standard or digital X-ray equipment to support osteoporosis screening, diagnosis, and therapy monitoring. In addition, the company provides mobile ECG and ultrasound solutions that provide patients with immediate access to its board-certified specialists; and medical devices. It serves organ procurement organizations, rural healthcare, and correctional healthcare industries. CompuMed, Inc. was founded in 1973 and is headquartered in Los Angeles, California.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.